Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1) (DIAGNODE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02352974
Recruitment Status : Completed
First Posted : February 2, 2015
Results First Posted : April 27, 2020
Last Update Posted : April 27, 2020
Sponsor:
Collaborators:
Swedish Child Diabetes Foundation
Ostergotland County Council, Sweden
Diamyd Medical AB
Information provided by (Responsible Party):
Johnny Ludvigsson, Linkoeping University

Brief Summary:

The objectives of the main study is to:

  • Evaluate the safety of giving GAD-Alum (Glutamic acid decarboxylase) (Diamyd) directly into lymph glands in combination with an oral vitamin D regimen
  • Evaluate how the above mentioned treatments influence the immune system and endogenous insulin secretion.

The objective of the sub-study is to:

  • Evaluate safety after a fourth injection with 4 μg GAD-Alum direct into an inguinal lymph gland in 3 adult patients from the main study
  • Evaluate how the above mentioned treatment influences the immune system and endogenous insulin secretion.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Drug: GAD-Alum Drug: Vitamin D Phase 1

Detailed Description:

Eligible patients will be treated with 4 µg GAD-Alum into an inguinal lymph gland at three occasions, with one month intervals in combination with Vitamin D (14 000 IU/week) for 4 months, starting 1 month prior to first GAD-Alum injection.

A sub-study will include three adult patients from the main study and evaluate safety after a fourth injection with 4 μg GAD-Alum into an inguinal lymph gland in combination with oral vitamin D intake. The Prolonged Extension Study Period is 12 months and will start 30,5 months after baseline.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd®) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen
Study Start Date : January 2015
Actual Primary Completion Date : October 2019
Actual Study Completion Date : October 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GAD-Alum+Vitamin D

GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals

Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days

Drug: GAD-Alum
Other Name: Diamyd

Drug: Vitamin D
Other Name: Calciferol




Primary Outcome Measures :
  1. Number of Subjects With Injection Site Reactions Month 1 [ Time Frame: Month 1 ]
    Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)

  2. Number of Subjects With Injection Site Reactions Month 2 [ Time Frame: Month 2 ]
    Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)

  3. Number of Subjects With Injection Site Reactions Month 3 [ Time Frame: Month 3 ]
    Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)

  4. Number of Subjects With Injection Site Reactions Month 32 [ Time Frame: Month 32, extension period ]
    Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching)


Secondary Outcome Measures :
  1. Mean Change in C-peptide AUC (Area Under the Curve) (Mean 120min) Value, Month 15 [ Time Frame: Baseline to month 15 at 0, 30, 60, 90, 120 minutes post-dose ]

    Change from baseline to month 15 in C-peptide AUC (Area Under the Curve) (mean 120min) value

    AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration


  2. Mean Change in C-peptide AUC(Mean 120min) Value, Month 30 [ Time Frame: Baseline to month 30 at 0, 30, 60, 90, 120 minutes post-dose ]

    Change from baseline to month 30 in C-peptide AUC(mean 120min) value

    AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration


  3. Mean Change in C-peptide AUC(Mean 120min) Value, Month 43 [ Time Frame: Baseline to month 43, extension period at 0, 30, 60, 90, 120 minutes post-dose ]

    Change from baseline to month 43 in C-peptide AUC(mean 120min) value

    AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration


  4. Mean Change in C-peptide 90-minute Value, Month 15 [ Time Frame: Baseline to month 15 ]
    Change from baseline to month 15 in C-peptide 90-minute value

  5. Mean Change in C-peptide 90-minute Value, Month 30 [ Time Frame: Baseline to month 30 ]
    Change from baseline to month 30 in C-peptide 90-minute value

  6. Mean Change in C-peptide 90-minute Value, Month 43 [ Time Frame: Baseline to month 43, extension period ]
    Change from baseline to month 43 in C-peptide 90-minute value

  7. Mean Change in Fasting C-peptide Value, Month 15 [ Time Frame: Baseline to month 15 ]
    Change from baseline to month 15 in fasting C-peptide value

  8. Mean Change in Fasting C-peptide Value, Month 30 [ Time Frame: Baseline to month 30 ]
    Change from baseline to month 30 in fasting C-peptide value

  9. Mean Change in Fasting C-peptide Value, Month 43 [ Time Frame: Baseline to month 43, extension period ]
    Change from baseline to month 43 in fasting C-peptide value

  10. Mean Change in HbA1c, Month 15 [ Time Frame: Baseline to month 15 ]
    Change from baseline to month 15 in HbA1c

  11. Mean Change in HbA1c, Month 30 [ Time Frame: Baseline to month 30 ]
    Change from baseline to month 30 in HbA1c

  12. Mean Change in HbA1c, Month 43 [ Time Frame: Baseline to month 43, extension period ]
    Change from baseline to month 43 in HbA1c

  13. External Insulin Dose, Baseline [ Time Frame: Baseline ]
    External insulin dose at baseline

  14. External Insulin Dose, Month 15 [ Time Frame: Month 15 ]
    External insulin dose at month 15

  15. External Insulin Dose, Month 30 [ Time Frame: Month 30 ]
    External insulin dose at month 30

  16. External Insulin Dose, Month 43 [ Time Frame: Month 43, extension period ]
    External insulin dose at month 43

  17. Mean IDAA1c Values, Baseline [ Time Frame: Baseline ]
    Insulin dose-adjusted HbA1c (IDAA1c)

  18. Mean IDAA1c Values, Month 15 [ Time Frame: Month 15 ]
    Insulin dose-adjusted HbA1c (IDAA1c)

  19. Mean IDAA1c Values, Month 30 [ Time Frame: Month 30 ]
    Insulin dose-adjusted HbA1c (IDAA1c)

  20. Mean IDAA1c Values, Month 43 [ Time Frame: Month 43, extension period ]
    Insulin dose-adjusted HbA1c (IDAA1c)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Informed consent given by patients
  2. Type 1 diabetes according to the ADA (American Diabetes Association) classification with < 6 months diabetes duration
  3. Age 12.00-29.99 years at diagnosis of Type 1 diabetes
  4. Fasting C-peptide ≥0.12 nmol/L
  5. Pos GADA(Antibodies to GAD with molecular mass 65,000) but < 50 000 random units
  6. Females must agree to avoid pregnancy and have a negative urine pregnancy test
  7. Patients of childbearing potential must agree to using adequate contraception, until 1 year after the last administration of GAD-Alum.

Exclusion Criteria:

  1. Previous or current treatment with immunosuppressant therapy (although topical or inhaled steroids are accepted)
  2. Continuous treatment with any inflammatory drug (sporadic treatment e.g. because of headache or in connection with fever a few days will be accepted)
  3. Treatment with any oral or injected anti-diabetic medications other than insulin
  4. Treatment with Vitamin D, marketed or not, or unwilling to abstain from such medication during the trial
  5. A history of anaemia or significantly abnormal haematology results at screening
  6. A history of epilepsy, head trauma or cerebro-vascular accident, or clinical features of continuous motor unit activity in proximal muscles
  7. Clinically significant history of acute reaction to vaccines or other drugs in the past
  8. Treatment with any vaccine, including influenza vaccine, within 4 months prior to planned first study drug dose or planned treatment with any vaccine up to 4 months after the last injection with study drug.
  9. Participation in other clinical trials with a new chemical entity within the previous 3 months
  10. Inability or unwillingness to comply with the provisions of this protocol
  11. A history of alcohol or drug abuse
  12. A significant illness other than diabetes within 2 weeks prior to first dosing
  13. Known human immunodeficiency virus (HIV) or hepatitis
  14. Females who are lactating or pregnant (the possibility of pregnancy must be excluded by urine βHCG (beta-human chorionic gonadotropin) on-site within 24 hours prior to the GAD-Alum treatment)
  15. Males or females not willing to use adequate contraception until 1 year after the last GAD-Alum treatment
  16. Presence of associated serious disease or condition, including active skin infections that preclude subcutaneous injection, which in the opinion of the investigator makes the patient non-eligible for the study
  17. Deemed by the investigator not being able to follow instructions and/or follow the study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02352974


Locations
Layout table for location information
Sweden
Linköping University
Linköping, Sweden
Sponsors and Collaborators
Johnny Ludvigsson
Swedish Child Diabetes Foundation
Ostergotland County Council, Sweden
Diamyd Medical AB
Investigators
Layout table for investigator information
Principal Investigator: Johnny Ludvigsson, Professor Linkoeping University
  Study Documents (Full-Text)

Documents provided by Johnny Ludvigsson, Linkoeping University:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Johnny Ludvigsson, MD, PhD, Professor, Linkoeping University
ClinicalTrials.gov Identifier: NCT02352974    
Other Study ID Numbers: DIAGNODE-1
First Posted: February 2, 2015    Key Record Dates
Results First Posted: April 27, 2020
Last Update Posted: April 27, 2020
Last Verified: April 2020
Keywords provided by Johnny Ludvigsson, Linkoeping University:
Diamyd
Diabetes
Juvenile Diabetes
Diabetes Type 1
Type 1 Diabetes
Autoimmune Diabetes
Insulin Dependent Diabetes
Type 1 Diabetes Mellitus
rhGAD65 (Recombinant Human GAD with molecular mass 65,000)
GAD65
GAD-Alum
Diabetes Mellitus
Diabetes mellitus Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Vitamin D
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Vitamin D
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents